Archived Facts

Posts Tagged ‘analyst’

Perrigo Co. has built competitive advantages and diversified its revenue sources to help sustain future growth, according to a Barrington Research analyst who upgraded the stock and issued a glowing review of prospects for the company, which makes store-brand over-the-counter drugs and infant formulas.

Incoming search terms:

Related Posts:

WellPoint Inc.’s second-quarter performance, which sent shares plummeting Wednesday, fuels some doubt about whether the health insurer can increase its enrollment without an acquisition and execute its business cleanly, according to a BMO Capital analyst.

Related Posts:

Nektar Therapeutics shares rose Wednesday after a Jefferies & Co. analyst started covering the stock with a “Buy” rating, pointing to its promising drug pipeline.

Related Posts:

Shares of drug developer ArQule Inc. rose Tuesday after an RBC Capital Markets analyst started covering the stock with an “Outperform” rating based on its experimental cancer drug tivantinib.

Incoming search terms:

Related Posts:

Manufacturing problems at a Novartis factory that triggered the recall of four popular medicines could cost the company between $ 560 million and $ 750 million in lost sales and productivity, a Wall Street analyst estimated Tuesday.

Related Posts:

Manufacturing problems at a Novartis factory that triggered the recall of four popular medicines could cost the company between $ 560 million and $ 750 million in lost sales and productivity, a Wall Street analyst estimated Tuesday.

Incoming search terms:

Related Posts:

Shares of Celldex Therapeutics Inc. added to its recent gains Friday after an analyst predicted success for the company’s brain cancer treatment rindopepimut, although he said it will be years until Celldex has late-state trial data supporting the drug.

Incoming search terms:

Related Posts:

Shares of drug and medical device maker Abbott Laboratories closed higher Tuesday after an analyst suggested the company is undervalued compared with other drugmakers.

Related Posts:

A Citi Investment Research analyst upgraded shares of Acorda Therapeutics Inc., saying the stock is trading at a fair price but could move higher.

Related Posts:

Shares of Infinity Pharmaceuticals Inc. traded higher Monday after a Piper Jaffray analyst upgraded the stock, saying he expects the stock to rise as investors wait for clinical data on a cancer drug candidate.

Related Posts: